Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

4.63
0.0000
Volume:- -
Turnover:- -
Market Cap:4.82M
PE:-0.33
High:4.63
Open:4.63
Low:4.63
Close:4.63
52wk High:13.20
52wk Low:3.29
Shares:1.04M
Float Shares:974.73K
Volume Ratio:4.33
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.1059
EPS(LYR):-19.1292
ROE:-68.21%
ROA:-30.19%
PB:0.38
PE(LYR):-0.24

Loading ...

Company Profile

Company Name:
Galmed Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.